T-Cell Receptor Optimization with Reinforcement Learning and Mutation Polices for Precision Immunotherapy

Ziqi Chen¹, Martin Renqiang Min^{2(\boxtimes)}, Hongyu Guo³, Chao Cheng⁴, Trevor Clancy⁵, and Xia Ning^{1,6,7(\boxtimes)}

 1 Computer Science and Engineering, The Ohio State University, Columbus, OH $\,$ 43210. USA

{ning.104}@osu.edu

- Machine Learning Department, NEC Labs, Princeton, NJ 08540, USA {rengiang}@nec-labs.com
- ³ Digital Technologies Research Centre, National Research Council Canada, Ontario, Canada
 - $^{4}\,$ Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
 - NEC Oncolmmunity AS, Oslo Cancer Cluster, Innovation Park, Ullernchausséen 64, 0379, Oslo, Norway
 - ⁶ Biomedical Informatics, The Ohio State University, Columbus, OH 43210, USA
- 7 Translational Data Analytics Institute, The Ohio State University, Columbus, OH $43210,\,\mathrm{USA}$

Abstract. T cells monitor the health status of cells by identifying foreign peptides displayed on their surface. T-cell receptors (TCRs), which are protein complexes found on the surface of T cells, are able to bind to these peptides. This process is known as TCR recognition and constitutes a key step for immune response. Optimizing TCR sequences for TCR recognition represents a fundamental step towards the development of personalized treatments to trigger immune responses killing cancerous or virus-infected cells. In this paper, we formulated the search for these optimized TCRs as a reinforcement learning (RL) problem, and presented a framework TCRPPO with a mutation policy using proximal policy optimization. TCRPPO mutates TCRs into effective ones that can recognize given peptides. TCRPPO leverages a reward function that combines the likelihoods of mutated sequences being valid TCRs measured by a new scoring function based on deep autoencoders, with the probabilities of mutated sequences recognizing peptides from a peptide-TCR interaction predictor. We compared TCRPPO with multiple baseline methods and demonstrated that TCRPPO significantly outperforms all the baseline methods to generate positive binding and valid TCRs. These results demonstrate the potential of TCRPPO for both precision immunotherapy and peptide-recognizing TCR motif discovery.

Keywords: T-cell Receptor \cdot Immunotherapy \cdot Reinforcement Learning \cdot Biological Sequence Design

1 Introduction

Immunotherapy is a fundamental treatment for human diseases, which uses a person's immune system to fight diseases [35,10,36]. In the immune system, immune response is triggered by cytotoxic T cells which are activated by the engagement of the T cell receptors (TCRs) with immunogenic peptides presented by Major Histocompatibility Complex (MHC) proteins on the surface of infected or cancerous cells. The recognition of these foreign peptides is determined by the interactions between the peptides and TCRs on the surface of T cells. This process is known as TCR recognition and constitutes a key step for immune response [9,12]. Adoptive T cell immunotherapy (ACT), which has been a promising cancer treatment, genetically modifies the autologous T cells taken from patients in laboratory experiments, after which the modified T cells are infused into patients' bodies to fight cancer. As one type of ACT therapies, TCR T cell (TCR-T) therapy directly modifies the TCRs of T cells to increase the binding affinities, which makes it possible to recognize and kill tumor cells effectively [27]. TCR is a heterodimeric protein with an α chain and a β chain. Each chain has three loops as complementary determining regions (CDR): CDR1, CDR2 and CDR3. CDR1 and CDR2 are primarily responsible for interactions with MHC, and CDR3 interacts with peptides [26]. The CDR3 of the β chain has a higher degree of variations and is therefore arguably mainly responsible for the recognition of foreign peptides [20]. In this paper, we focused on the optimization of the CDR3 sequence of β chain in TCRs to enhance their binding affinities against peptide antigens, and we conducted the optimization through novel reinforcement learning. The success of our approach will have the potential to guide TCR-T therapy design. For the sake of simplicity, when we refer to TCRs in the rest of the paper, we mean the CDR3 of β chain in TCRs.

Despite the significant promise of TCR-T therapy, optimizing TCRs for therapeutic purposes remains a time-consuming process, which typically requires exhaustive screening for high-affinity TCRs, either in vitro or in silico. To accelerate this process, computational methods have been developed recently to predict peptide-TCR interactions [33], leveraging the experimental peptide-TCR binding data [30,34] and TCR sequences [6]. However, these peptide-TCR binding prediction tools cannot immediately direct the rational design of new high-affinity TCRs. Existing computational methods for biological sequence design include search-based methods [3], generative methods [19,16], optimization-based methods [14] and reinforcement learning (RL)-based methods [2,31]. However, all these methods generate sequences without considering additional conditions such as peptides, and thus cannot optimize TCRs tailored to recognizing different peptides. In addition, these methods do not consider the validity of generated sequences, which is important for TCR optimization as valid TCRs should follow specific characteristics [18].

In this paper, we presented a new reinforcement-learning (RL) framework based on proximal policy optimization (PPO) [29], referred to as TCRPPO ⁸, to computationally optimize TCRs through a mutation policy. In particular,

⁸ The code is available at https://github.com/ninglab/TCRPPO

TCRPPO learns a joint policy to optimize TCRs customized for any given peptides. In TCRPPO, we designed a new reward function that measures both the likelihoods of the mutated sequences being valid TCRs, and the probabilities of the TCRs recognizing peptides. To measure TCR validity, we developed a TCR auto-encoder, referred to as TCR-AE, and utilized reconstruction errors from TCR-AE and also its latent space distributions, quantified by a Gaussian Mixture Model, to calculate novel validity scores. To measure peptide recognition, we leveraged a state-of-the-art peptide-TCR binding predictor ERGO [33] to predict peptide-TCR binding. Please note that TCRPPO is a flexible framework, as ERGO can be replaced by any other binding predictors [5,37]. In addition, we designed a novel buffering mechanism, referred to as Buf-Opt, to revise TCRs that are difficult to optimize. We conducted extensive experiments using 7 million TCRs from TCRdb [6], 10 peptides from McPAS [34] and 15 peptides from VDJDB [30]. Our experimental results demonstrated that TCRPPO can substantially outperform the best baselines with best improvement of 45.04% and 52.89% in terms of generating qualified TCRs with high validity scores and high recognition probabilities, over McPAS and VDJDB peptides, respectively. Figure 1 presents the overall architecture of TCRPPO.

2 Related Work


Existing methods developed for biological sequence design include search-based methods, deep generative methods, optimization-based methods and RL-based methods. Among search-based methods, the classical evolutionary search [3] uses an evolution strategy to randomly mutate the sequences and select desired ones in an iterative way. Among generative methods, Killoran et al. [19] optimized the latent embeddings of DNA sequences learned from a variational autoencoder towards better properties. Gupta et al. [16] used generative adversarial networks (GANs) to generate DNA sequences and selected the generated ones with desired properties to further optimize GANs. Among optimization-based methods, Gonzalez et al. [14] used a Gaussian process model to emulate the production rates of a certain protein across different gene designs in living cells, and then optimized the gene designs to improve the production rates using Bayesian optimization. Both the above generative methods and optimization methods aim at optimizing the biological sequences without any additional conditions, As a consequence, these methods are not applicable to our TCR optimization problem. In our problem, the optimization of TCRs must be tailored to given peptides, because TCRs binding to different peptides have different characteristics.

Despite the success of RL on many applications, there remains limited work of applying RL to biological sequence design. Angermueller et al. [2] developed a model-based RL method for biological sequence design using PPO to improve the sample efficiency, where the policy is trained over a simulator model learned to approximate the reward function. Skwark et al. [31] then leveraged a RL method based on PPO to discover a potential Covid-19 cure. Their method aims at identifying the variants of human angiotensin-converting enzyme (ACE2) protein sequence that have higher binding affinities against the SARS-CoV-2 spike protein than the original ACE2 protein. Our TCRPPO also applies PPO with a

4 Chen et al.

mutation policy to optimize TCR sequences. However, TCRPPO is fundamentally different from previous methods in three aspects. First, TCRPPO learns a joint policy to optimize the TCRs customized for any given peptides. In addition, TCRPPO employs a comprehensive reward function to simultaneously optimize the validity and the recognition probability of the TCRs against the peptides. TCRPPO also leverages a buffering mechanism to generalize the optimization capability of TCRPPO to TCRs that are hard to optimize, or peptides with fewer positive binding TCRs.

3 Methods






Fig. 1. Model Architecture of TCRPPO

3.1 Problem Definition

Fig. 2. Data Flow for TCRPPO and TCR-AE training and testing

In this paper, the recognition ability of a TCR sequence against the given peptides is measured by a recognition probability, denoted as s_r . The likelihood of a sequence being a valid TCR is measured by a score, denoted as s_v . A qualified TCR is defined as a sequence with $s_r > \sigma_r$ and $s_v > \sigma_c$, where σ_r and σ_c are pre-defined thresholds (σ_r =0.9 and σ_c =1.2577, as discussed in Appendix A.2 and A.4.4, respectively). The goal of TCRPPO is to mutate the existing TCR sequences that have low recognition probability against the given peptide, into qualified ones. A peptide p or a TCR sequence c is represented as a sequence of its amino acids $\langle o_1, o_2, \cdots, o_i, \cdots, o_l \rangle$, where o_i is one of the 20 types of natural amino acids at the position i in the sequence, and l is the sequence length. We formulated the TCR mutation process as a Markov Decision Process (MDP) $M = \{S, A, P, \mathcal{R}\}$ containing the following components:

- S: the state space, in which each state $s \in S$ is a tuple of a potential TCR sequence c and a peptide p, that is, s = (c, p). Subscript t ($t = 0, \dots, T$) is used to index step of s, that is, $s_t = (c_t, p)$. Please note that c_t may not be a valid TCR. A state s_t is a terminal state, denoted as s_T , if it contains a qualified c_t , or t reaches the maximum step limit T. Please also note that p will be sampled at s_0 and will not change over time t,
- \mathcal{A} : the action space, in which each action $\mathbf{a} \in \mathcal{A}$ is a tuple of a mutation site i and a mutant amino acid o, that is, $\mathbf{a} = (i, o)$. Thus, the action will mutate the amino acid at position i of a sequence $c = \langle o_1, o_2, \cdots, o_i, \cdots, o_l \rangle$ into another amino acid o. Note that o has to be different from o_i in c.
- \mathcal{P} : the state transition probabilities, in which $\mathcal{P}(s_{t+1}|s_t, \mathbf{a}_t)$ specifies the probability of next state s_{t+1} at time t+1 from state s_t at time t with the

action \mathbf{a}_t . In our problem, the transition to s_{t+1} is deterministic, that is $\mathcal{P}(s_{t+1}|s_t,\mathbf{a}_t)=1$.

- \mathcal{R} : the reward function at a state. In TCRPPO, all the intermediate rewards at states s_t $(t = 0, \dots, T - 1)$ are 0; only the final reward at s_T is used to guide the optimization.

3.2 Mutation Policy Network

TCRPPO mutates one amino acid in a sequence c at a step to modify c into a qualified TCR. Specifically, at the initial step t=0, a peptide p is sampled as the target, and a valid TCR c_0 is sampled to initialize $s_0=(c_0,p)$; at a state $s_t=(c_t,p)$ (t>0), the mutation policy network of TCRPPO predicts an action \mathbf{a}_t that mutates one amino acid of c_t to modify it into c_{t+1} that is more likely to lead to a final, qualified TCR bound to p. TCRPPO encodes the TCRs and peptides in a distributed embedding space. It then learns a mapping between the embedding space and the mutation policy, as discussed below.

Encoding of Amino Acids Following the idea in Chen *et al.* [7], we represented each amino acid o by concatenating three vectors: 1) \mathbf{o}^b , the corresponding row of o in the BLOSUM matrix, 2) \mathbf{o}^o , the one-hot encoding of o, and 3) \mathbf{o}^d , the learnable embedding, that is, o is encoded as $\mathbf{o} = \mathbf{o}^b \oplus \mathbf{o}^o \oplus \mathbf{o}^d$, where \oplus represents the concatenation operation. We used such a mixture of encoding methods to enrich the representations of amino acids within c and p.

Embedding of States We embedded $s_t = (c_t, p)$ via embedding its associated sequences c_t and p. For each amino acid $o_{i,t}$ in c_t , we embedded $o_{i,t}$ and its context information in c_t into a hidden vector $\mathbf{h}_{i,t}$ using a one-layer bidirectional LSTM [15] as below,

$$\overrightarrow{\mathbf{h}}_{i,t}, \overrightarrow{\mathbf{c}}_{i,t} = \text{LSTM}(\mathbf{o}_{i,t}, \overrightarrow{\mathbf{h}}_{i-1,t}, \overrightarrow{\mathbf{c}}_{i-1,t}; \overrightarrow{W});$$

$$\overleftarrow{\mathbf{h}}_{i,t}, \overleftarrow{\mathbf{c}}_{i,t} = \text{LSTM}(\mathbf{o}_{i,t}, \overleftarrow{\mathbf{h}}_{i+1,t}, \overleftarrow{\mathbf{c}}_{i+1,t}; \overleftarrow{W});$$

$$\mathbf{h}_{i,t} = \overrightarrow{\mathbf{h}}_{i,t} \oplus \overleftarrow{\mathbf{h}}_{i,t}$$

$$(1)$$

where $\overrightarrow{\mathbf{h}}_{i,t}$ and $\overleftarrow{\mathbf{h}}_{i,t}$ are the hidden state vectors of the *i*-th amino acid in c_t ; $\overrightarrow{\mathbf{c}}_{i,t}$ and $\overleftarrow{\mathbf{c}}_{i,t}$ are the memory cell states of *i*-th amino acid; \overrightarrow{W} and \overleftarrow{W} are the learnable parameters of the two LSTM directions, respectively; and $\overrightarrow{\mathbf{h}}_{0,t}, \overleftarrow{\mathbf{h}}_{l_c,t},$ $\overrightarrow{\mathbf{c}}_{0,t}$ and $\overleftarrow{\mathbf{c}}_{l_c,t}$ (l_c is the length of c_t) are initialized with random vectors. With the embeddings of all the amino acids, we defined the embedding of c_t as the concatenation of hidden vectors at the two ends, that is, $\mathbf{h}_t = \overrightarrow{\mathbf{h}}_{l_c,t} \oplus \overleftarrow{\mathbf{h}}_{0,t}$. We embedded a peptide sequence into a hidden vector \mathbf{h}^p using another bidirectional LSTM in the same way.

Action Prediction To predict the action $\mathbf{a}_t = (i, o)$ at time t, TCRPPO needs to make two predictions: 1) the position i of current c_t where \mathbf{a}_t needs to occur; 2) the new amino acid o that \mathbf{a}_t needs to place with at position i. To measure "how likely" the position i in c_t is the action site, TCRPPO uses the following network:

$$f(i) = \mathbf{w}^{\mathsf{T}}(\operatorname{ReLU}(W_1\mathbf{h}_{i,t} + W_2\mathbf{h}^p)) / (\sum_{j=1}^{l_c} \mathbf{w}^{\mathsf{T}}(\operatorname{ReLU}(W_1\mathbf{h}_{j,t} + W_2\mathbf{h}^p))), \quad (2)$$

where $\mathbf{h}_{i,t}$ is the latent vector of $o_{i,t}$ in c_t (Equation 1); \mathbf{h}^p is the latent vector of p; \mathbf{w}/W_j (j=1,2) are the learnable vector/matrices. Thus, TCRPPO measures the probability of position i being the action site by looking at its context encoded in $\mathbf{h}_{i,t}$ and the peptide p. The predicted position i is sampled from the probability distribution from Equation 2 to ensure necessary exploration.

Given the predicted position i, TCRPPO needs to predict the new amino acid that should replace o_i in c_t . TCRPPO calculates the probability of each amino acid type being the new replacement as follows:

$$g(o) = \operatorname{softmax}(U_1 \times \operatorname{ReLU}(U_2 \mathbf{h}_{i,t} + U_3 \mathbf{h}^p)), \tag{3}$$

where U_j (j=1,2,3) are the learnable matrices; softmax(·) converts a 20-dimensional vector into probabilities over the 20 amino acid types. The replacement amino acid type is then determined by sampling from the distribution, excluding the original type of $o_{i,t}$.

3.3 Potential TCR Validity Measurement

Leveraging the literature [40,1], we designed a novel scoring function to quantitatively measure the likelihood of a given sequence c being a valid TCR (i.e., to calculate s_v), which will be part of the reward of TCRPPO. Specifically, we trained a novel auto-encoder model, denoted as TCR-AE, from only valid TCRs. We used the reconstruction accuracy of a sequence in TCR-AE to measure its TCR validity. The intuition is that since TCR-AE is trained from only valid TCRs, its encoding-decoding process will obey the "rules" of true TCR sequences, and thus, a non-TCR sequence could not be well reproduced from TCR-AE. However, it is still possible that a non-TCR sequence can receive a high reconstruction accuracy from TCR-AE, if TCR-AE learns some generic patterns shared by TCRs and non-TCRs and fails to detect irregularities, or TCR-AE has high model complexity [22,40]. To mitigate this, we additionally evaluated the latent space within TCR-AE using a Gaussian Mixture Model (GMM), hypothesizing that non-TCRs would deviate from the dense regions of TCRs in the latent space.

TCR-AE Figure 1 presents the auto-encoder TCR-AE. TCR-AE uses a bidirectional LSTM to encode an input sequence c into \mathbf{h}' by concatenating the last hidden vectors from the two LSTM directions (similarly as in Equation 1). Please note that this bidirectional LSTM is independent of the mutation policy network in TCRPPO. \mathbf{h}' is then mapped into a latent embedding \mathbf{z}' as follows,

$$\mathbf{z}' = W^z \mathbf{h}',\tag{4}$$

which will be decoded back to a sequence \hat{c} via a decoder. The decoder has a single-directional LSTM that decodes \mathbf{z}' by generating one amino acid at a time as follows,

$$\mathbf{h}'_{i}, \mathbf{c}'_{i} = \text{LSTM}(\hat{\mathbf{o}}_{i-1}, \mathbf{h}'_{i-1}, \mathbf{c}'_{i-1}; W'); \quad \hat{o}_{i} = \text{softmax}(U' \times \text{ReLU}(U'_{1}\mathbf{h}'_{i} + U'_{2}\mathbf{z}')),$$
(5)

where $\hat{\mathbf{o}}_{i-1}$ is the encoding of the amino acid \hat{o}_{i-1} that is decoded from step i-1; W' is the parameter. The LSTM starts with a zero vector $\mathbf{o}_0 = \mathbf{0}$ and $\mathbf{h}_0 = W^h \mathbf{z}'$. The decoder infers the next amino acid by looking at the previously decoded amino acids encoded in \mathbf{h}_i' and the entire prospective sequence encoded in \mathbf{z}' .

Please note that TCR-AE is trained from TCRs, independently of TCRPPO and in an end-to-end fashion. Teacher forcing [39] is applied during training to feed the ground truth amino acids as inputs to predict the next amino acid, and thus cross entropy loss is applied on each amino acid to optimize TCR-AE. As a stand-alone module, TCR-AE is used to calculate the score s_v . The input sequence c to TCR-AE is encoded using only BLOSUM matrix as we found empirically that BLOSUM encoding can lead to a good reconstruction performance and a fast convergence compared to other combinations of encoding methods.

Reconstruction-based score With a well-trained TCR-AE, we calculated the reconstruction-based TCR validity score of a sequence c as follows,

$$r_r(c) = 1 - \text{lev}(c, \text{TCR-AE}(c))/l_c \tag{6}$$

where TCR-AE(c) represents the reconstructed sequence of c from TCR-AE; lev(.) is the Levenshtein distance, an edit-distance-based metric, between c and TCR-AE(c); l_c is the length of c. Higher $r_r(c)$ indicates higher probability of c being a valid TCR. Please note that when TCR-AE is used in testing, the length of the reconstructed sequence might not be the same as the input c, because TCR-AE could fail to accurately predict the end of the sequence, leading to either too short or too long reconstructed sequences. Therefore, we normalized the Levenshtein distance using the length of input sequence l_c similarly to Snover $et\ al.\ [32]$. Please note that $r_r(c)$ could be negative when the distance is greater than the sequence length. The negative values will not affect the use of the scores (i.e., negative $r_r(c)$ indicates very different TCR-AE(c) and c).

Density Estimation-based Score To better distinguish valid TCRs from invalid ones, TCRPPO also conducts a density estimation over the latent space of \mathbf{z}' (Equation 4) using GMM. For a given sequence c, TCRPPO calculates the likelihood score of c falling within the Gaussian mixture region of training TCRs as follows,

 $r_d(c) = \exp\left(1 + \frac{\log P(\mathbf{z}')}{\tau}\right) \tag{7}$

where $\log P(\mathbf{z}')$ is the log-likelihood of the latent embedding \mathbf{z}' ; τ is a constant used to rescale the log-likelihood value ($\tau = 10$). We carefully selected the parameter τ such that 90% of TCRs can have $r_d(c)$ above 0.5. As we do not have invalid TCRs, we cannot use classification-based scaling methods such as Platt scaling [23] to calibrate the log likelihood values to probabilities.

TCR Validity Scoring Combining the reconstruction-based scoring and density estimation-based scoring, we developed a new scoring method to measure TCR validity as follows: $s_v(c) = r_r(c) + r_d(c)$. (8)

This method is used to evaluate if a sequence is likely to be a valid TCR and is used in the reward function.

3.4 TCRPPO Learning

Final Reward We defined the final reward for TCRPPO based on s_r and s_v scores as follows,

$$\mathcal{R}(c_T, p) = s_r(c_T, p) + \alpha \min(0, s_v(c_T) - \sigma_c)$$
(9)

where $s_r(c_T, p)$ is the predicted recognition probability by ERGO, σ_c is a threshold that c_T is very likely to be a valid TCR; and α is the hyperparameter used to control the tradeoff between s_r and s_v ($\alpha = 0.5$).

Policy Learning We adopted the proximal policy optimization (PPO) [29] to optimize the policy network as discussed in Section 3.2. The objective function of PPO is defined as follows:

$$\max_{\boldsymbol{\Theta}} L^{\text{CLIP}}(\boldsymbol{\Theta}) = \hat{\mathbb{E}}_{t}[\min(r_{t}(\boldsymbol{\Theta})\hat{A}_{t}, \text{clip}(r_{t}(\boldsymbol{\Theta}), 1 - \epsilon, 1 + \epsilon)\hat{A}_{t})],$$
where $r_{t}(\boldsymbol{\Theta}) = \frac{\pi_{\boldsymbol{\Theta}}(a_{t}|s_{t})}{\pi_{\boldsymbol{\Theta}_{\text{old}}}(a_{t}|s_{t})},$
(10)

where $\boldsymbol{\Theta}$ is the set of learnable parameters of the policy network and $r_t(\boldsymbol{\Theta})$ is the probability ratio between the action under current policy $\pi_{\boldsymbol{\Theta}}$ and the action under previous policy $\pi_{\boldsymbol{\Theta}_{\text{old}}}$. Here, $r_t(\boldsymbol{\Theta})$ is clipped to avoid moving r_t outside of the interval $[1 - \epsilon, 1 + \epsilon]$. \hat{A}_t is the advantage at timestep t computed with the generalized advantage estimator [28], measuring how much better a selected action is than others on average:

$$\hat{A}_t = \delta_t + (\gamma \lambda)\delta_{t+1} + \dots + (\gamma \lambda)^{T-t+1}\delta_{T-1},\tag{11}$$

where $\gamma \in (0,1)$ is the discount factor determining the importance of future rewards; $\delta_t = r_t + \gamma V(s_{t+1}) - V(s_t)$ is the temporal difference error in which $V(s_t)$ is a value function; $\lambda \in (0,1)$ is a parameter used to balance the bias and variance of $V(s_t)$. Here, $V(\cdot)$ uses a multi-layer perceptron (MLP) to predict the future return of current state s_t from the peptide embedding \mathbf{h}^p and the TCR embedding \mathbf{h}_t . The objective function of $V(\cdot)$ is as follows:

$$\min_{\boldsymbol{\Theta}} L^{V}(\boldsymbol{\Theta}) = \hat{\mathbb{E}}_{t}[(V(\mathbf{h}_{t}, \mathbf{h}^{p}) - \hat{R}_{t})^{2}], \tag{12}$$

where $\hat{R}_t = \sum_{i=t+1}^T \gamma^{i-t} r_i$ is the rewards-to-go. Because we only used the final rewards, that is $r_i = 0$ if $i \neq T$, we calculated \hat{R}_t with $\hat{R}_t = \gamma^{T-t} r_T$. We also added the entropy regularization loss $H(\Theta)$, a popular strategy used for policy gradient methods [21,29], to encourage the exploration of the policy. The final objective function of TCRPPO is defined as below,

$$\min_{\boldsymbol{\Theta}} L(\boldsymbol{\Theta}) = -L^{\text{CLIP}}(\boldsymbol{\Theta}) + \alpha_1 L^V(\boldsymbol{\Theta}) - \alpha_2 H(\boldsymbol{\Theta}), \tag{13}$$

where α_1 and α_2 are two hyperparameters controlling the tradeoff among the PPO objective, the value function and the entropy regularization term.

Reward-Informed Buffering and Re-optimization TCRPPO implements a novel buffering and re-optimizing mechanism, denoted as Buf-Opt, to deal with TCRs that are difficult to optimize, and to generalize its optimization capacity to more, diverse TCRs. To optimize TCRs, various number of mutations will be

applied to get the binding TCRs. For TCRs requiring more mutations, it could be more difficult for TCRPPO to optimize; and thus re-optimizing these TCRs enables TCRPPO to explore more actions for the optimization of difficult TCRs, instead of being overwhelmed by relatively simple cases. This mechanism includes a buffer, which memorizes the TCRs that cannot be optimized to qualify. These hard sequences and the corresponding peptides will be sampled from the buffer again following the probability distribution below, to be further optimized by TCRPPO,

$$S(c,p) = \xi^{(1-\mathcal{R}(c_T,p))}/\Sigma. \tag{14}$$

In Equation 14, S measures how difficult to optimize c against p based on its final reward $\mathcal{R}(c_T,p)$ in the previous optimization, ξ is hyper-parameter ($\xi=5$ in our experiments), and Σ converts S(c,p) as a probability. It is expected that by doing the sampling and re-optimization, TCRPPO is better trained to learn from hard sequences, and also the hard sequences have the opportunity to be better optimized by TCRPPO. In case a hard sequence still cannot be optimized to qualify, it will have 50% chance of being allocated back to the buffer. In case the buffer is full (size 2,000 in our experiments), the sequences earliest allocated in the buffer will be removed. We referred to the TCRPPO with Buf-Opt as TCRPPO+b.

4 Experimental Settings

4.1 Datasets

We selected peptides and TCR sequences for the training and testing of TCRPPO and TCR-AE. Figure 2 summaries the peptides and TCRs used in our experiments.

Peptides To test TCRPPO, we first identified a set of peptides that TCRPPO needs to optimize TCR sequences for. We aimed at selecting the peptides which are very likely to have reliable peptide-TCR binding predictions, such that their binding predictions can serve to test TCRPPO's optimized TCRs against the respective peptides. We identified such peptides from two databases: McPAS [34] and VDJDB [30], which have experimentally validated TCR-peptide binding pairs. We applied the autoencoder-based ERGO models [33] on McPAS and VDJDB (McPAS and VDJDB have pre-specified training and testing sets for each peptide), and selected the peptides which have AUC values above 0.9 on their respective testing sets. This resulted in 10 peptides selected from McPAS, denoted as $\mathcal{P}_{\text{McPAS}}$, and 15 peptides selected from VDJDB, denoted as $\mathcal{P}_{\text{VDJDB}}$, with lengths ranging from 8 to 21, as presented in Appendix Table A.1. Additional discussion on peptides is available in Appendix A.1.

TCR sequences We then selected TCR sequences that TCRPPO needs to optimize against each of the peptides selected as above. We selected such sequences from the TCRdb database [6], which contains 277 million human TCR sequences, each with a TCR- β sequence. Here, we used TCRdb, not McPAS or VDJDB, because TCRdb's sequences are valid TCRs and have no information on their binding affinities with the selected peptides. Therefore, these valid TCRs can be used to train TCR-AE to calculate s_v . Meanwhile, since TCRdb is much larger than McPAS (4,528 TCRs) and VDJDB (50,049 TCRs), it is very likely that the s_v calculated

from the TCR-AE, which is trained over TCRdb data, will be independent of the s_r calculated from ERGO, which is trained on McPAS or VDJDB, avoiding possible correlation between s_v and s_r as in the reward (Equation 9).

We selected all the TCRs with lengths below 27 (ERGO can only predict sequences of length 27 or shorter) from TCRdb, resulting in 7,331,105 unique TCR- β sequences. Figure A.1 presents the distribution of lengths of TCRs in TCRdb. As shown in Figure A.1, the most common length of TCRs is 15. Additional discussion on the length of TCRs is available in Appendix A.1. Among these selected sequences, we sampled 50K sequences, denoted as the validation set S_v , to test and validate s_v ; within these 50K sequences, we again sampled 1K sequences, denoted as the testing set S_{tst} , to test TCRPPO performance once it is well trained. The remaining selected sequences (i.e., not in the validation set), denoted as the training set S_{trn} , are used to train TCRPPO; they are also used to train TCR-AE.

4.2 Experimental Setup

For all the selected peptides from a same database (i.e., 10 peptides from McPAS, 15 peptides from VDJDB), we trained one TCRPPO agent, which optimizes the training sequences (i.e., 7,281,105 TCRs in Figure 2) to be qualified against one of the selected peptides. The ERGO model trained on the corresponding database (the same ERGO model also used to select the peptides from the database as in Section 4.1) will be used to test recognition probabilities s_r for the TCRPPO agent. Please note that as in Springer $et\ al.\ [33]$, one ERGO model is trained for all the peptides in each database (i.e., one ERGO predicts TCR-peptide binding for multiple peptides). Thus, the ERGO model is suitable to test s_r for multiple peptides in our setting. Also note that we trained one TCRPPO agent corresponding to each database, because peptides and TCRs in these two databases are very different, demonstrated by the inferior performance of an ERGO trained over the two databases together, and discussed in Springer $et\ al.\ [33]$.

TCRPPO mutates each sequence up to 8 steps (i.e., T=8). In TCRPPO training, an initial TCR sequence (i.e., c_0 in s_0) is randomly sampled from \mathcal{S}_{trn} , and will be mutated in the following states; a peptide p is randomly sampled at s_0 , and remains the same in the following states (i.e., $s_t = (c_t, p)$). Once a TCRPPO is well trained from \mathcal{S}_{trn} , it will be tested on \mathcal{S}_{tst} . We set the dimensions of the hidden layers (e.g., hidden layers of action prediction networks) as 256, and the dimensions of latent embeddings (e.g., \mathbf{h}^p , \mathbf{h}_t) as 128 (i.e., half of the hidden dimensions). Other hyper-parameters and the details of hyper-parameter selection of the TCR mutation environment, the policy network and the RL agent are available in Appendix A.2.

4.3 Baseline Methods

We compared the TCRPPO method and TCRPPO+b with multiple baseline methods of two primary categories: 1) generative methods that generate a new TCR in its entirety, and 2) mutation-based methods that optimize TCRs via mutating amino acids of existing TCRs. For generative methods, we used two baseline methods including Monte Carlo tree search (MCTS) [8] and a variational autoencoder with backpropagation (BP-VAE) [13]. For mutation-based methods, we used three baseline methods to mutate each TCR sequence up to 8 steps and stop the

Table 1 Overall Performance Comparison

Dataset	Dataset Method	%b	edist	$\overline{s_v}\left(\mathcal{C}_q ight)$	$\overline{s_v}\left(\mathcal{C}_v\right)$	$\overline{s_r} \; (\mathcal{C}_q)$	$\overline{s_r}$ (C_v)	% ^	# <i>R</i>
	RS	0.05 ± 0.12	,	1.46 ± 0.16	1.46 ± 0.16 1.73 ± 0.17 0.95 ± 0.01	0.95 ± 0.01	0.05 ± 0.00	95.22 ± 0.45	1
	MCTS BP-VAE	0.01 ± 0.03 0.04 ± 0.09		1.38 ± 0.00 1.31 ± 0.02	1.34 ± 0.03 1.34 ± 0.02	1.34±0.03 0.93±0.00 1.34±0.02 0.95±0.02	0.09±0.09 0.09±0.04	0.59 ± 0.28 6.86 ± 2.52	200
$\mathcal{P}_{ ext{McPAS}}$	$rac{ ext{RM (n=5)}}{ ext{RM (n=10)}}$	1.27±2.09 2.15±3.86 20.58±17.85	2.88±1.50 1.49±0.07 3.04± 1.48 1.50±0.11 5.10± 1.09 1.46±0.03	1.49±0.07 1.50±0.11 1.46±0.03	$\begin{array}{c} 1.54 \pm 0.02 \\ 1.52 \pm 0.02 \\ 1.44 \pm 0.02 \end{array}$		0.18±0.09 0.26±0.11 0.62±0.12	99.36±0.21 99.84±0.12 99.98±0.04	39 77 74
	Genetic TCRPPO	25.18±21.28 5.16±1.05 1.46±0.03 1.46±0.02 0.93±0.01 0.69±0.12 25.89±29.60 5.15± 2.02 1.55±0.19 1.51±0.17 0.97±0.03 0.76±0.27 36 52+30.25 5.37±1.81 1.55±0.17 1.53±0.17 0.96±0.03 0.83±0.21	5.16 ± 1.05 5.15 ± 2.02 5.37 ± 1.81	1.46±0.03 1.55±0.19	5.16± 1.05 1.46±0.03 1.46±0.02 0.93±0.01 0.69±0.12 5.15± 2.02 1.55±0.19 1.51±0.17 0.97±0.03 0.76±0.27 5.37±1.81 1.55±0.17 1.53±0.17 0.96±0.03 0.83±0.23	0.93±0.01 0.97±0.03	0.69±0.12 0.76±0.27	100.00±0.00 65.23±12.47 75.83+9.46	166
	RS		1	1.58±0.20	1.58±0.20 1.73±0.28 0.94±0.02	0.94±0.02	0.03±0.03	95.02±0.46	-
	MCTS BP-VAE	0.00 ± 0.00 0.08 ± 0.12	1 1	0.00 ± 0.00 1.33 ± 0.03	1.35 ± 0.03 1.35 ± 0.01	0.00 ± 0.00 0.95 ± 0.03	0.05±0.06 0.05±0.03	0.46 ± 0.09 18.46 ± 5.13	200
$\mathcal{P}_{ ext{VDJDB}}$	$rac{ ext{RM (n=5)}}{ ext{RM (n=10)}}$ $ ext{Greedy}$	2.15±1.82 4.41±3.72 31.81±17.09 38.57±20.57	2.84±1.47 1.48±0.09 3.03±1.52 1.48±0.07 5.01±1.12 1.47±0.03 5.07±1.07 1.48±0.03	1.48±0.09 1.48±0.07 1.47±0.03 1.48+0.03	1.55±0.01 1.52±0.02 1.44±0.02 1.47±0.02	0.94±0.02 0.94±0.01 0.93±0.01 0.94+0.01	0.16±0.06 0.24±0.08 0.64±0.09 0.72+0.09	99.33±0.21 99.86±0.08 99.96±0.06	39 77 71 71
	TCRPPO TCRPPO+b	. 10		1.51±0.19 1.65±0.20	5.34±1.58 1.51±0.19 1.51±0.19 0.96±0.02 0.87±0.18 5.20±1.69 1.65±0.20 1.63±0.19 0.97±0.02 0.89±0.17	0.96±0.02 0.97±0.02	0.87±0.18 0.89±0.17	69.99 ± 11.74 82.41 ± 5.54	1

Columns represent: q%: the percentage of qualified TCR sequences; edist: the edit distance between the original TCR sequences and the mutated qualified TCR sequences; $\overline{s_v}(\mathcal{C}_q)/\overline{s_v}(\mathcal{C}_v)$: the average s_v scores over the TCRs in set C_q/C_v ; $\overline{s_r}(C_q)/\overline{s_r}(C_v)$: the average s_r probabilities over the TCRs in set C_q/C_v ; v%: the percentage of valid TCR sequences. # \mathcal{R} : the average number of calls to calculate \mathcal{R} functions. Values $x \pm y$ represent mean x and standard deviation y. ":" not applicable. The "n" value in RM indicates that RM is done n times over each sequence. mutation once a qualified TCR is generated, including random mutation (RM), greedy mutation (Greedy) and genetic mutation (Genetic) [38]. In addition, we used a random selection method (RS) as another baseline to randomly sample a TCR from TCRdb, which helps quantify the space of valid TCRs. More details about baseline methods are available in Appendix A.3.

4.4 Evaluation Metrics

We evaluated all the methods using six metrics including: (1) qualification rate q%, which measures the percentage of qualified TCRs (Section 3.1) among all the output TCRs; (2) edit distance between c_0 and c_T (edist), which measures sequence difference between c_0 and qualified c_T ; (3) average TCR validity score $\overline{s_v}$ over valid TCRs or over qualified TCRs; (4) average recognition probability $\overline{s_r}$ over valid TCRs or over qualified TCRs; (5) validity rate v%, which measures the percentage of valid TCRs (Section 3.1) among all the output TCRs; (6) average number of calls to \mathcal{R} calculation (# \mathcal{R}) (Equation 9) over all the generated TCRs, which estimates the efficiency of methods. We calculated the metrics over two different sets of output TCRs: (1) the set of valid TCRs \mathcal{C}_v : $\mathcal{C}_v = \{c|s_v(c) > \sigma_c\}$; (2) the set of qualified TCRs \mathcal{C}_q : $\mathcal{C}_q = \{c|s_r(c) > \sigma_c, c \in \mathcal{C}_v\}$.

5 Experimental Results

5.1 Comparison on TCR Optimization Methods

Overall Comparison Table 1 presents the overall comparison among all the methods over $\mathcal{P}_{\text{McPAS}}$ and $\mathcal{P}_{\text{VDJDB}}$. In $\mathcal{P}_{\text{McPAS}}$, TCRPPO methods achieve overall the best performance: in terms of q%, TCRPPO achieves $25.89\pm29.60\%$, which slightly outperforms the best q% from the baseline method Genetic $(25.18\pm21.28\%)$. TCRPPO+b achieves the best q% at $36.52\pm30.25\%$ among all the methods, which is 45.04% better than the best from the baseline methods $(25.18\pm21.28\%)$ from Genetic). TCRPPO+b achieves so with a few \mathcal{R} calls ($\#\mathcal{R}=7$). In $\mathcal{P}_{\text{VDJDB}}$, TCRPPO methods also achieve overall the best performance: in terms of q%, TCRPPO and TCRPPO+b outperform the best baseline Genetic by 18.80% and 52.89%.

Among the qualified TCRs (C_q) for \mathcal{P}_{McPAS} , TCRPPOand TCRPPO+b methods achieve the highest $\overline{s_v}$ values on average $(1.55\pm0.19 \text{ for TCRPPO}; 1.55\pm0.17 \text{ for}$ TCRPPO+b), with above 6% improvement from those of Genetic, which achieves the best q% among all the baseline methods. Note that qualified TCRs must have s_v above σ_c , which is set as 1.2577 as discussed in Appendix A.4.4. The significant high s_v values from TCRPPO methods demonstrate that TCRPPO is able to generate qualified TCRs that are highly likely to be valid TCRs. In terms of s_r among qualified TCRs, TCRPPO methods have $\overline{s_r}(\mathcal{C}_q)$ value 0.97 ± 0.03 , above the σ_r . Note that $\sigma_r = 0.9$, a very high threshold for s_r to determine TCR-peptide binding, is actually a very tough constraint. The fact that TCRPPO methods can survive this constraint with substantially high q\% and highly likely valid TCRs as results demonstrates the strong capability of TCRPPO methods. In addition, TCRPPO methods need a few number of calls to calculate \mathcal{R} (i.e., 7 for TCRPPO, compared to 166 for Genetic), indicating that TCRPPO is very efficient in identifying qualified TCRs. In $\mathcal{P}_{\text{VDJDB}}$, we observed very similar trends as those in \mathcal{P}_{McPAS} .

Among all the baseline methods, RS randomly selects a valid TCR from TCRdb, given that some TCRs in TCRdb may already qualify. Thus, it is a naive baseline for all the other methods. It has $\mathbf{v}\%$ around 95%, corresponding to how our s_v threshold σ_c is identified (by 95 percentile true positive rate) as discussed in Appendix A.4.4. On average, among all valid TCRs, about 0.05% (q% in RS) TCRs are qualified TCRs. RM, Greedy, Genetic and TCRPPO methods substantially outperform this baseline method.

Comparison among Mutation-based Methods RM, Greedy, Genetic, TCRPPO and TCRPPO+b are mutation-based methods: they start from a valid TCR from TCRdb, and optimize the TCR by mutating its amino acids. Among all the mutation-based methods, TCRPPO and TCRPPO+b outperform others as discussed above. Below we only focused on $\mathcal{P}_{\text{McPAS}}$, as similar trends exist on $\mathcal{P}_{\text{VDJDB}}$.

In $\mathcal{P}_{\text{McPAS}}$, RM underperforms all the other mutation-based methods: it has q% below 3% on average, but has very high v% (close to 100%). RM uses \mathcal{R} to select randomly mutated sequences, which decomposes to its s_v and its s_r components. RM starts from valid TCRs with high s_v already, but low s_r in general. During random mutation, s_r cannot be easily improved as no knowledge or informed guidance is used to direct the mutation towards better s_r . Therefore, the s_v component in \mathcal{R} will dominate, leading to that the final selected, best mutated sequence tends to have high s_v to satisfy high \mathcal{R} . Such best mutated sequence tends to occur after only a few random mutations, since as shown in Appendix A.4.4, random mutations can quickly decrease s_v values. Thus, the qualified sequences produced from RM tend to be more similar to the initial TCRs (edist is small, around 3; high v% as $99.36\pm0.21\%$), their s_v values are high (close to 1.5; highest among all mutation-based methods) but q% is low due to hardly improved s_r values.

In $\mathcal{P}_{\text{McPAS}}$, Greedy has a better q% (20.58±17.85%) than RM and also a high v% (99.98±0.04%). Greedy leverages a greedy strategy to select the random mutation that gives the best \mathcal{R} at the current step. Thus, it leverages some guidance on s_r improvement based on \mathcal{R} , and can improve s_r values compared to RM. As in Table 1, it has better $s_r(\mathcal{C}_v)$ value (0.62±0.12) for valid TCRs. Meanwhile, Greedy explores a large sequence space, allowing its to identify more valid TCRs, leading to high v% (99.98±0.04), high q% (20.58±17.85; also due to better s_r improvement) but more diverse results (edist = 5.10±1.09) than RM.

Genetic is the second best mutation-based method on $\mathcal{P}_{\text{McPAS}}$, after TCRPPO methods. Genetic explores a sequence space even larger than that in Greedy, and uses \mathcal{R} to guide next mutations also in a greedy way. Thus, it enjoys the opportunity to reach more, potentially qualified TCRs, demonstrated by high edist (5.16 ± 1.05) indicating diverse sequences, and thus achieves a better q% $(25.18\pm21.28\%)$ than Greedy, even better than that of TCRPPO, and a high v% $(100.00\pm0.00\%)$, at a significant cost of many more calls to calculate \mathcal{R} . Even though, it still significantly underperforms TCRPPO+b in terms of q% and qualities of qualified TCRs as discussed earlier.

Comparison between Mutation-based Methods and Generation-based Methods Overall, mutation-based methods substantially outperform generation-

based methods. For example, in terms of q%, mutation-based methods (excluding random mutation RM) has an average q% 22.88% in $\mathcal{P}_{\text{McPAS}}$, compared to 0.03% of the generation-based methods (MCTS and BP-VAE). In addition to the superior performance, mutation-based methods have strong biological relevance that make them very suitable and practical for TCR-T based precision immunotherapy, in which they can be readily employed to optimize existing TCRs found in patient's TCR repertoire. However, any promising TCRs generated from generation-based methods have to be either synthesized, which could be both very costly and technically challenging, or mutated from existing TCRs that are similar to the generated TCRs in their amino acids. Detailed discussions on generation-based methods are available in Appendix A.4.1.

5.2 Evaluation on Optimized TCR Sequences




Fig. 3. Optimized TCR patterns for McPAS peptides (A); TCR distances (B).

Figure 3A presents the entropy of amino acid distributions at each sequence position among the length-15 TCRs for each $\mathcal{P}_{\texttt{McPAS}}$ peptide. Here the TCRs are optimized by TCRPPO with respect to the McPAS peptides. Figure 3A clearly shows some common patterns among all the optimized TCRs. For example, the first three positions and last four positions tend to have high conservation. TCRs for some peptides (e.g., "SSPPMFRV", "ASNENMETM", and "RFYK-TLRAEQASQ") have high variations at internal regions. Similar patterns are also observed among the binding TCRs for other peptides in VDJDB 9 .

Figure 3B presents the difference between qualified TCRs optimized by TCRPPO and existing TCRs. It presents the distribution of Hamming distances between qualified TCRs (length 15) for peptide "RFYKTLRAEQASQ" and their most similar (in terms of Hamming distance) TCRs that are known to bind to this peptide in McPAS; and the distribution of Hamming distances between qualified TCRs for this peptide and their most similar TCRs in TCRdb. This figure demonstrates that the qualified TCRs by TCRPPO are actually different from known binding TCRs, but there are TCRs similar to them existing in TCRdb. This can be meaningful for precision immunotherapy, as TCRPPO can produce diverse TCR candidates that are different from known TCRs, leading to a novel sequence space; meanwhile, these TCR candidates actually have similar human TCRs available for further medical evaluation and investigation purposes.

Additional analyses are available in Appendix A.4, such as the overview of amino acid distributions of TCRs, the patterns for binding TCRs and the comparison on TCR detection. Specifically, we found that TCRPPO can successfully

⁹ https://vdjdb.cdr3.net/motif

learn the patterns of TCRs (Appendix A.4.2); we also found that TCRPPO can identify the specific binding patterns which are more conserved than the real binding patterns (Appendix A.4.3). We also found that our s_v scoring method successfully distinguishes TCRs from non-TCRs in Appendix A.4.4.

6 Conclusions and Outlook

In this paper, we presented a reinforcement learning framework to optimize TCRs for more effective TCR recognition, which has the potential to guide TCR engineering therapy. Our experimental results in comparison with generation-based methods and mutation-based methods on optimizing TCRs demonstrate that TCRPPO outperforms the baseline methods. Our analysis on the TCRs generated by TCRPPO demonstrates that TCRPPO can successfully learn the conservation patterns of TCRs. Our experiments on the comparison between the generated TCRs and existing TCRs demonstrate that TCRPPO can generate TCRs similar to existing human TCRs, which can be used for further medical evaluation and investigation. Our results in TCR detection comparison show that the s_v score in our framework can very effectively detect non-TCR sequences. Our analysis on the distribution of s_v scores over mutations demonstrates that TCRPPO mutates sequences along the trajectories not far away from valid TCRs.

Our proposed TCRPPO is a modular and flexible framework. Thus, the TCR-AE and ERGO scoring functions in the reward design can be replaced with other predictors trained on large-scale data when available. Also, TCRPPO can be further improved from the following perspectives. First, the recognition probabilities of TCRs considered in our paper are based on a peptide-TCR binding predictor (i.e., ERGO) rather than experimental validation. Therefore, testing the generated qualified TCR candidates in a wet-lab will be needed ultimately to validate the interactions between TCRs and peptides. Moreover, when the predicted recognition probabilities are not sufficiently accurate, TCRPPO learned from unreliable rewards could be inaccurate, resulting in generating TCRs that could not recognize the given peptide. Thus, it could be an interesting and challenging future work to incorporate the reliabilities of predictions in the reward function of TCRPPO, so that the effect of unreliable recognition probabilities can be alleviated. Finally, TCRPPO only considers the CDR3 of β chain in TCRs, while other regions of TCRs, though not contributing most to interactions between TCRs and peptides, are not considered. In this sense, incorporating other regions of TCRs (e.g., CDR3 of alpha chains) could be an interesting future work.

References

- 1. Abati, D., Porrello, A., Calderara, S., Cucchiara, R.: Latent space autoregression for novelty detection. In: Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR) (June 2019)
- Angermüller, C., Dohan, D., Belanger, D., Deshpande, R., Murphy, K., Colwell, L.: Model-based reinforcement learning for biological sequence design. In: 8th International Conference on Learning Representations, ICLR 2020, Addis Ababa, Ethiopia, April 26-30, 2020 (2020)

- Arnold, F.H.: Design by directed evolution. Accounts of Chemical Research 31(3), 125–131 (feb 1998)
- 4. Auer, P., Cesa-Bianchi, N., Fischer, P.: Machine Learning 47(2/3), 235–256 (2002)
- 5. Cai, M., Bang, S., Zhang, P., Lee, H.: ATM-TCR: TCR-epitope binding affinity prediction using a multi-head self-attention model. Frontiers in Immunology 13 (jul 2022)
- Chen, S.Y., Yue, T., Lei, Q., Guo, A.Y.: TCRdb: a comprehensive database for t-cell receptor sequences with powerful search function. Nucleic Acids Research 49(D1), D468–D474 (sep 2020)
- Chen, Z., Min, M.R., Ning, X.: Ranking-based convolutional neural network models for peptide-MHC class i binding prediction. Frontiers in Molecular Biosciences 8 (may 2021)
- 8. Coulom, R.: Efficient selectivity and backup operators in monte-carlo tree search. In: Computers and Games, pp. 72–83. Springer Berlin Heidelberg (2007)
- Craiu, A., Akopian, T., Goldberg, A., Rock, K.L.: Two distinct proteolytic processes in the generation of a major histocompatibility complex class i-presented peptide. Proceedings of the National Academy of Sciences 94(20), 10850–10855 (sep 1997)
- Esfahani, K., Roudaia, L., Buhlaiga, N., Rincon, S.D., Papneja, N., Miller, W.: A review of cancer immunotherapy: From the past, to the present, to the future. Current Oncology 27(12), 87–97 (apr 2020)
- 11. Freeman, J.D., Warren, R.L., Webb, J.R., Nelson, B.H., Holt, R.A.: Profiling the t-cell receptor beta-chain repertoire by massively parallel sequencing. Genome Research 19(10), 1817–1824 (jun 2009)
- Glanville, J., Huang, H., Nau, A., Hatton, O., Wagar, L.E., Rubelt, F., Ji, X., Han, A., Krams, S.M., Pettus, C., et al.: Identifying specificity groups in the t cell receptor repertoire. Nature 547(7661), 94–98 (2017)
- Gómez-Bombarelli, R., Wei, J.N., Duvenaud, D., Hernández-Lobato, J.M., Sánchez-Lengeling, B., Sheberla, D., Aguilera-Iparraguirre, J., Hirzel, T.D., Adams, R.P., Aspuru-Guzik, A.: Automatic chemical design using a data-driven continuous representation of molecules. ACS Central Science 4(2), 268–276 (jan 2018)
- González, J., Longworth, J., James, D.C., Lawrence, N.D.: Bayesian optimization for synthetic gene design (2015)
- Graves, A., Schmidhuber, J.: Framewise phoneme classification with bidirectional LSTM and other neural network architectures. Neural Networks 18(5-6), 602–610 (jul 2005)
- 16. Gupta, A., Zou, J.: Feedback GAN for DNA optimizes protein functions. Nature Machine Intelligence 1(2), 105–111 (feb 2019)
- 17. Hinton, G.E., Vinyals, O., Dean, J.: Distilling the knowledge in a neural network. CoRR abs/1503.02531 (2015)
- 18. Hou, X., Wang, M., Lu, C., Xie, Q., Cui, G., Chen, J., Du, Y., Dai, Y., Diao, H.: Analysis of the repertoire features of TCR beta chain CDR3 in human by high-throughput sequencing. Cellular Physiology and Biochemistry **39**(2), 651–667 (2016)
- Killoran, N., Lee, L.J., Delong, A., Duvenaud, D., Frey, B.J.: Generating and designing DNA with deep generative models. CoRR abs/1712.06148 (2017)
- La Gruta, N.L., Gras, S., Daley, S.R., Thomas, P.G., Rossjohn, J.: Understanding the drivers of mhc restriction of t cell receptors. Nature Reviews Immunology 18(7), 467–478 (2018)

- Mnih, V., Badia, A.P., Mirza, M., Graves, A., Lillicrap, T., Harley, T., Silver, D., Kavukcuoglu, K.: Asynchronous methods for deep reinforcement learning. In: Proceedings of The 33rd International Conference on Machine Learning. vol. 48, pp. 1928–1937. PMLR, New York, New York, USA (20–22 Jun 2016)
- 22. Pang, G., Shen, C., Cao, L., Hengel, A.V.D.: Deep learning for anomaly detection: A review. ACM Comput. Surv. **54**(2) (mar 2021)
- Platt, J.: Probabilistic outputs for support vector machines and comparisons to regularized likelihood methods. Advances in large margin classifiers 10(3), 61–74 (mar 1999)
- Raffin, A., Hill, A., Gleave, A., Kanervisto, A., Ernestus, M., Dormann, N.: Stable-baselines3: Reliable reinforcement learning implementations. Journal of Machine Learning Research 22(268), 1–8 (2021)
- Ren, J., Liu, P.J., Fertig, E., Snoek, J., Poplin, R., DePristo, M.A., Dillon, J.V., Lakshminarayanan, B.: Likelihood Ratios for Out-of-Distribution Detection. Curran Associates Inc., Red Hook, NY, USA (2019)
- Rossjohn, J., Gras, S., Miles, J.J., Turner, S.J., Godfrey, D.I., McCluskey, J.: T cell antigen receptor recognition of antigen-presenting molecules. Annual review of immunology 33, 169–200 (2015)
- 27. Sadelain, M., Rivière, I., Riddell, S.: Therapeutic t cell engineering. Nature 545(7655), 423–431 (2017)
- Schulman, J., Moritz, P., Levine, S., Jordan, M., Abbeel, P.: High-dimensional continuous control using generalized advantage estimation. In: Proceedings of the International Conference on Learning Representations (ICLR) (2016)
- 29. Schulman, J., Wolski, F., Dhariwal, P., Radford, A., Klimov, O.: Proximal policy optimization algorithms. CoRR abs/1707.06347 (2017)
- Shugay, M., Bagaev, D.V., Zvyagin, I.V., Vroomans, R.M., Crawford, J.C., Dolton, G., et al.: VDJdb: a curated database of t-cell receptor sequences with known antigen specificity. Nucleic Acids Research 46(D1), D419–D427 (sep 2017)
- 31. Skwark, M.J., Carranza, N.L., Pierrot, T., Phillips, J., Said, S., Laterre, A., Kerkeni, A., Sahin, U., Beguir, K.: Designing a prospective COVID-19 therapeutic with reinforcement learning. CoRR abs/2012.01736 (2020)
- 32. Snover, M., Dorr, B., Schwartz, R., Micciulla, L., Makhoul, J.: A study of translation edit rate with targeted human annotation. In: Proceedings of the 7th Conference of the Association for Machine Translation in the Americas: Technical Papers. pp. 223–231. Cambridge, Massachusetts, USA (Aug 8-12 2006)
- Springer, I., Besser, H., Tickotsky-Moskovitz, N., Dvorkin, S., Louzoun, Y.: Prediction of specific TCR-peptide binding from large dictionaries of TCR-peptide pairs. Frontiers in Immunology 11 (aug 2020)
- 34. Tickotsky, N., Sagiv, T., Prilusky, J., Shifrut, E., Friedman, N.: McPAS-TCR: a manually curated catalogue of pathology-associated t cell receptor sequences. Bioinformatics 33(18), 2924–2929 (may 2017)
- 35. Verdegaal, E.M.E., de Miranda, N.F.C.C., Visser, M., Harryvan, T., van Buuren, M.M., Andersen, R.S., Hadrup, S.R., van der Minne, C.E., Schotte, R., Spits, H., Haanen, J.B.A.G., Kapiteijn, E.H.W., Schumacher, T.N., van der Burg, S.H.: Neoantigen landscape dynamics during human melanoma—t cell interactions. Nature 536(7614), 91–95 (jun 2016)
- Waldman, A.D., Fritz, J.M., Lenardo, M.J.: A guide to cancer immunotherapy: from t cell basic science to clinical practice. Nature Reviews Immunology 20(11), 651–668 (may 2020)

- 37. Weber, A., Born, J., Martínez, M.R.: TITAN: T-cell receptor specificity prediction with bimodal attention networks. Bioinformatics **37**(Supplement_1), i237–i244 (jul 2021)
- 38. Whitley, D.: A genetic algorithm tutorial. Statistics and Computing 4(2) (jun 1994)
- 39. Williams, R.J., Zipser, D.: A learning algorithm for continually running fully recurrent neural networks. Neural Computation ${\bf 1}(2),\,270-280$ (jun 1989)
- 40. Zong, B., Song, Q., Min, M.R., Cheng, W., Lumezanu, C., Cho, D., Chen, H.: Deep autoencoding gaussian mixture model for unsupervised anomaly detection. In: International Conference on Learning Representations (2018)

A.1 Data Analyses

We listed the selected peptides from McPAS and VDJDB in Table A.1. As shown in Table A.1, these selected peptides are very different. For example, the average edit distance between pairs of peptides in $\mathcal{P}_{\text{McPAS}}$ and $\mathcal{P}_{\text{VDJDB}}$ are 10.84 and 9.14, respectively, demonstrating the diversity of peptides compared with the average length of peptides in $\mathcal{P}_{\text{McPAS}}$ and $\mathcal{P}_{\text{VDJDB}}$ (10.90 and 9.67). Comparing $\mathcal{P}_{\text{McPAS}}$ with $\mathcal{P}_{\text{VDJDB}}$, we found that 6 peptides included in $\mathcal{P}_{\text{McPAS}}$ are also included in $\mathcal{P}_{\text{VDJDB}}$, which could be due to the data overlapping between McPAS and VDJDB [30].

We also listed the distribution of length of TCRs in TCRdb in Figure A.1. We found that the most common length of TCRs is 15; and TCRs with 13, 14, 15, and 16 lengths account for over 10% of the entire database. In this manuscript, our analyses focus on TCRs of length 13, 14, 15 and 16.

Table A.1
Peptides in McPAS and VDJDB that TCRs are optimized to bind to

$\mathcal{P}_{ t McPAS}$	$\mathcal{P}_{ extsf{VDJDB}}$
ASNENMETM	ASNENMETM
ATDALMTGY	ATDALMTGY
HGIRNASFI	CTPYDINQM
HPKVSSEVHI	FPRPWLHGL
MEVGWYRSPFSRVVHLYRNGK	FRDYVDRFYKTLRAEQASQE
RFYKTLRAEQASQ	GTSGSPIVNR
SSLENFRAYV	HGIRNASFI
SSPPMFRV	LSLRNPILV
SSYRRPVGI	NAITNAKII
YSEHPTFTSQY	$\operatorname{SQLLNAKYL}$
	SSLENFRAYV
	SSPPMFRV
	SSYRRPVGI
	STPESANL
	TTPESANL

A.2 Parameter setup

We listed the hyper-parameters of the TCR mutation environment, the policy network and the RL agent in Table A.2. We selected an optimal set of hyperparameters including the discount factor, the entropy coefficient and the maximum steps by a grid search, according to the average rewards of the final 10 iterations. Particularly, we set the maximum steps T as 8 steps, as we empirically found that it can lead to the highest average final rewards. We set the parameter α as 0.5 for the tradeoff between validity scores and recognition probabilities, as we empirically found that different α values could lead to comparable results.




Fig. A.1. The distribution of length of TCRs in TCRdb.

Table A.2 Experimental Setup for TCRPPO

description	value
$ \overline{\text{maximum steps } T} $	8
threshold of s_r	0.9
threshold of s_v	1.2577
discount factor γ	0.9
latent dimension of $\overrightarrow{\mathbf{h}}_i/\overleftarrow{\mathbf{h}}_i/\mathbf{h}^p$	256
hidden dimension of policy & value networks	128
hidden layers of policy & value networks	2
number of steps per iteration	5,120
batch size for policy update	64
number of epochs per iteration	10
clip range	0.2
learning rate	3e-4
coefficient for value function α_1	0.5
coefficient for entropy regularization α_2	0.01

We also constructed a validation set by sampling 1,000 TCRs from the test set of TCR-AE; these TCRs are not included in the test set of TCRPPO. We then selected the hyperparameters including the hidden dimension of policy network and value networks and the ratio of difficult initial state from Buf-Opt that the corresponding models achieve the maximum qualified percentage q%. Among three options [64, 128, 256], the optimal hidden dimensions of policy and value networks for McPAS and VDJDB are 128. We set the latent dimension of $\overrightarrow{\mathbf{h}}_i/\overrightarrow{\mathbf{h}}_i/\overrightarrow{\mathbf{h}}_i/\overrightarrow{\mathbf{h}}_i/\overrightarrow{\mathbf{h}}_i$ to be double of the optimal hidden dimensions, that is, 256. In terms of encodings of amino acids, we set the dimension of learnable embeddings as 20, which is the same with the dimensions of BLOSUM embeddings and one-hot encodings; that is, the total dimension of amino acid encodings is 60. In terms of ratios of difficult initial state, the optimal ratios for McPAS and VDJDB are 0.2 and 0.1, respectively. We set the threshold for recognition probability s_r as 0.9, which is demonstrated as a proper threshold as it can lead to 47.04% and 56.48% at

true positive rate and 0.16% and 0.30% at false positive rate, respectively, for selected peptides in McPAS and VDJDB. In the implementation of TCRPPO, for each iteration, we ran 20 environments in parallel for 256 timesteps and collect trajectories with 5,120 timesteps in total. We trained TCRPPO for 1e7 timesteps (i.e., 1954 iterations). We set all the other hyper-parameters for the RL agent as the default hyper-parameters provided by the stable-baselines3 [24], as we found little performance improvement from tuning these parameters. We trained the models using a Tesla P100 GPU and a CPU on Red Hat Enterprise 7.7. It took 9-10 hours to train a TCRPPO model. With the trained model available, on a single GPU and a single CPU core, optimizing 1,000 TCRs for a single peptide using TCRPPO takes 160.5 seconds, which is faster than that of the state-of-the-art baseline Genetic (i.e., 207.8s).

For TCR-AE, we selected an optimal set of hyperparameters including the dimension of hidden layers and the dimension of latent layers. According to the reconstruction accuracy on the validation set, we set the dimension of hidden layers in TCR-AE to be 64, and the dimension of latent layers to be 16. At each step, we randomly sampled 256 TCR sequences from TCRdb, and trained the TCR-AE for 100,000 steps. This TCR-AE is with high reconstruction accuracy on our validation set, which is 94.6%, and thus can be used to provide reliable reconstruction-based scores for TCR sequences.

A.3 Baseline methods

We describe the baseline methods used in the main text as follows,

- MCTS: Monte Carlo Tree Search. Given a peptide p, MCTS generates TCR sequences by adding one amino acid step by step until reaching the maximum length of 20 amino acids or with the recognition probability s_r greater than σ_r . All the generated peptides with no less than 10 amino acids will be evaluated by ERGO. The approach of MCTS is described in Algorithm A.1. At each step, the amino acid to be added is determined by the Upper Confidence Bound algorithm (see equation in line 12 of Algorithm A.1) to balance exploration and exploitation [4]. The hyper-parameter c_{puct} is set as 0.5. For each peptide, the number of rollout N is set as 1,000, as all the methods including TCRPPO generate 1,000 TCRs for each peptide. At the beginning of search, we initialize the sequence with "C", as all the TCRs in TCRdb begin with "C". We collected all the generated TCRs during the search process, and calculated the metrics listed in Table 1 over the 1,000 TCRs with the highest reward values for each peptide.
- BP-VAE: Back Propagation with the Variational Autoencoder. In BP-VAE, a VAE model is first pre-trained to convert TCR sequences of variable lengths into continuous latent embeddings of a fixed size with a single-layer LSTM. Then, a student model with the pre-trained VAE is employed to distill knowledge from ERGO via learning the recognition probabilities produced by ERGO from the latent embeddings [17]. Note that during this fine-tuning process, the parameters of pre-trained VAE will also be updated. With the well-trained

student model, BP-VAE can generate TCRs by optimizing the latent embeddings of TCRs through gradient ascent to maximize the predicted recognition probabilities from the student model. The decoded TCR sequences with the prediction from student model greater than σ_r will be evaluated by \mathcal{R} function. We fine-tuned the hyper-parameters and set the dimension of hidden layers for VAE as 64, the dimension of latent embeddings as 8, the batch size as 256, the initial coefficient for KL loss as 0.05 and the initial learning rate as 0.005. We increased the coefficient by 0.05 every 1e4 steps until reaching the maximum coefficient limit 0.3; we also decreased the learning rate by 10 percent every 5,000 steps until reaching the minimum learning rate limit 0.0001. We pre-trained the VAE model for 2e6 steps. We then fine-tune the VAE model with the student model for 50,000 steps. During the inference, we set the maximum step t for gradient ascent as 50 and the learning rate of gradient ascent as 0.05. Similar to MCTS, we collected all the generated TCRs and calculated the metrics over the 1,000 TCRs with the highest reward values for each peptides.

- RM: random mutation. It randomly mutates a sequence one amino acid at a step up to 8 steps, each step leading to an intermediate mutated sequence; it does so for each sequence n times, generating 8n mutated sequences. It selects the mutated sequence with the highest \mathcal{R} as the final output.
- Greedy: greedy mutation. It randomly mutates one amino acid of c_t at step t, and does this 10 times, generating 10 mutated sequences which are all one-amino-acid different from c_t . It selects the one with best \mathcal{R} among the 10 sequences as the next sequence to further mutate.
- Genetic: genetic mutation. It randomly mutates each sequence in the population (size n=5) five times, each at one site, generating five mutated sequences. Among all the mutated sequences for all the sequences in the population, Genetic selects the top-n sequences with the best \mathcal{R} as the next population.

A.4 Additional Results

A.4.1 Discussion on Comparison among Generation-based Methods

Generation-based methods MCTS and BP-VAE on average very much underperform mutation-based methods. Both MCTS and BP-VAE hardly generate any qualified TCRs (very low q%: $0.01\pm0.03\%$ for MCTS and $0.04\pm0.09\%$ for BP-VAEin $\mathcal{P}_{\text{McPAS}}$). MCTS explores potentially the entire sequence space, including both valid TCRs and non-TCRs. Although it uses \mathcal{R} to guide the search, with substantially more calls to calculate \mathcal{R} than other methods, due to the fact that valid TCRs may only occupy an extreme small portion of the entire sequence space, it is extremely challenging for MCTS to find qualified TCRs. In $\mathcal{P}_{\text{VDJDB}}$, MCTS even cannot find any qualified TCR for all the peptides within 1,000 rollouts, and thus has zero values at $\overline{s_v}(\mathcal{C}_q)$ and $\overline{s_r}(\mathcal{C}_q)$. An estimation using TCRdb over all possible length-15 sequence space results at most $\frac{1.817,721}{20^{15}} = 5.55 \times 10^{-12}\%$ TCRs being valid

Algorithm A.1 Monte Carlo Tree Search for TCR Generation

```
Require: \mathcal{R}(.,p), c_{puct}, N, minLen, maxLen
1: U = \{\}
2: for n = 1 to N do
         \triangleright root node of search tree T
        c_0 = \text{``C''}; \tau^n = \{\}
 3:
        for l = 1 to maxLen do
 4:
            ▷ expansion
 5:
            for each amino acid o do
 6:
                c_l' = c_{l-1} + o
 7:
                if c'_l \notin T then
                    W(c'_l) = 0; N(c'_l) = 0; P(c'_l) = 0
 8:
9:
                    add c'_l as a child of c_{l-1} into T
10:
                 end if
11:
            end for
            select a child c_l of c_{l-1} with the maximum value a_k = \arg \max_{l} \frac{W(c_l)}{N(c_l)} +
12:
    c_{puct} * \sqrt{\frac{2N(C_{l-1})}{1+N(C_l)}}
            if N(c_l) = 0 and length(c_l) \ge \minLen then
13:
                 P(c_l) = \mathcal{R}(c_l, p)
14:
             end if
15:
            N(c_l) = N(c_l) + 1
16:
17:
            add c_l into \tau^n
            if c_l is qualified then
18:
                 break
19:
            end if
20:
        end for
21:
         ▶ backpropagation
22:
        r^n = 0
23:
        for each c_l along path \tau^n from c_{\text{maxLen}} to c_0 do
            if P(c_l) > r^n then
24:
                r^n = c_l.P
25:
            end if
26:
            W(c_l) = W(c_l) + r^n
27:
        end for
28:
         ⊳ output
29:
        add c_l with maximum P(c_l) into U
30: end for
31: return U
```

in the sequence space. Therefore, it is possible that MCTS ends at a region in the sequence space with q% even worse than random selection method RS.

Similarly, BP-VAE also has a minimum q% (0.04±0.09%). BP-VAE encodes valid TCRs into its latent space, and uses a predictor in the latent space, which is trained to approximate ERGO, to guide the search of an optimal latent vector.

This vector could correspond to a binding TCR and then is decoded to a TCR sequence. However, there is a phenomenon that is observed in other VAE-based generative approaches [13]: while the latent vector is searched under a guidance to maximize desired properties, its decoded instance does not always have the properties or are not even valid. This phenomenon also appears in BP-VAE: the decoded TCRs are not qualified most of the times. This might be due to the propagation or magnification of the errors from the predictor in the latent space, or the exploration in the latent space ends at a region far away from that of valid TCRs. However, theoretical justification behind VAE-based generative approaches is out of the scope of this paper.

A.4.2 Overview of Amino Acid Distributions of TCRs

Valid TCRs, regardless of their binding affinities against any peptides, have certain patterns [11]. For example, the first and last amino acids have to be 'C' and 'F', respectively. Figure A.2 presents the patterns among different TCRs of length 13, 14, 15 and 16. For TCRs of length 15 (most common TCR length), the left panel of Figure A.2C shows the enrichment of different amino acids at different positions among peptides in TCRdb. Recall that TCRdb has 277 million valid human TCRs, and thus the patterns in the left panel of Figure A.2C are very representative of the common patterns among valid TCRs. The middle panel of Figure A.2C shows that the patterns among the TCRs that TCRPPO produces for peptides in McPAS are similar to those of TCRs in TCRdb. For example, 'G' is one of the most frequent amino acids on positions 6-9; the first three positions and the last four positions of optimized TCRs have patterns highly similar to those in TCRdb TCRs. Similar observations are also for the TCRs that TCRPPO produces for peptides in $\mathcal{P}_{\text{VD,IDB}}$ as in the right panel of Figure A.2C. Please note that in TCRPPO, we do not impose any rules to reserve amino acids at the ends of sequences when generating TCRs with both high validity and high recognition probability against given peptides; clearly, TCRPPO successfully learns the pattern. In Figure A.2A, A.2B and A.2D, the same observations are for TCRs of length 13, 14 and 16 as in Figure A.2C for TCRs of length 15. For example, the first three positions and the last three positions of generated TCRs have very similar patterns with those in TCRdb (i.e., dominated by "CAS" and "QYF"). This indicates that TCRPPO also successfully learn the patterns for TCRs of other lengths.

A.4.3 Amino Acid Distributions of Binding TCRs

Figure A.3 presents the patterns among binding TCRs in McPAS dataset (left) and the generated TCRs of different lengths for peptide "RFYKTLRAEQASQ" in McPAS. Particularly, as in Figure A.3C, the patterns among binding TCRs in McPAS are similar to those of generated TCRs. For example, the most frequent amino acids at position 6 - 9 in generated TCRs (i.e., "R", "A", "R", "G") are also one of the most frequent amino acids at corresponding positions in known binding TCRs. Similar observations are also for generated TCRs of different lengths.




Fig. A.2. The distribution of amino acids at different positions for all the TCRs in TCRdb (left panel) and the generated TCRs for $\mathcal{P}_{\text{McPAS}}$ (middle panel) and $\mathcal{P}_{\text{VDJDB}}$ (right panel) of length 13 (A), length 14 (B), length 15 (C) and length 16 (D).

This demonstrates that TCRPPO can successfully identify the patterns of binding TCRs. In addition to the similar patterns, we also observe the inconsistent patterns between known binding TCRs and generated TCRs. For example, the generated TCRs are highly conserved on position 4, that is, most fourth amino acids are "H"; this conservation pattern does not exist in known binding TCRs. Please note that "H" also exists on position 4 among known binding TCRs as in Figure A.3A. One reason for inconsistency between generated TCRs and known binding TCRs could be that only limited percentage of binding TCRs are with predicted recognition probabilities greater than 0.9, resulting in that generated TCRs are more conserved on some patterns.

Figure A.4 presents the distribution of action types produced by TCRPP0+b for TCRs of length 15 binding to the peptide "RFYKTLRAEQASQ". As shown in Figure A.4, positions 5, 7, 9 in the TCRs prefer to be Histidine ("H"), Alanine ("A"), Arginine ("R") and Glycine ("G"). Since Alanine and Glycine are non-polar and hydrophobic, the hydrophobic effect tends to be strong around these positions. On the other hand, position 4 prefer to be Histidine, which has a positive charge on its side chain. Additionally, positions 5, 6, 8 in the TCRs prefer to be Arginine, which is hydrophilic and has a positive charge on its side chain. This shows that the binding pocket around these positions is more electrophilic which favors the interaction with amino acids with positive charges.




Fig. A.3. The distribution of amino acids at different positions for TCRs binding to the peptide "RFYKTLRAEQASQ" in McPAS (left panel) and generated TCRs (right panel) of length 13 (A), length 14 (B), length 15 (C) and length 16 (D).




Fig. A.4. The distribution of action types produced by TCRPPO+b for TCRs of length 15 binding to the peptide "RFYKTLRAEQASQ".

A.4.4 Comparison on TCR Detection

We compared our s_v scoring method (Equation 8) and the likelihood ratio method [25], denoted as 1r, on distinguishing TCRs from non-TCRs. The likelihood ratio method is one of the state-of-the-art methods on out-of-distribution (OOD) detection for genomic sequences. To compare s_v and 1r, we generated 50,000 sequences for each TCR in \mathcal{S}_{tst} , with the two ends conserved to 'C' and 'F' respectively as in valid TCRs, and all the other internal amino acids fully random. These generated, random sequences will be considered as non-TCRs. The conserved 'C' and 'F' ends among the non-TCRs ensure that they are not trivially separable from TCRs simply due to the ends. We compared s_v and 1r scores to detect TCRs from such non-TCRs, and present their distributions in Figure A.5.




Fig. A.5. Distributions of s_v scores (**A**) and lr scores (**B**).




Fig. A.6. Distributions of s_v scores of TCRs with random mutations (**A**) and mutations from TCRPPO (**B**); the red lines represent the threshold value σ_v .

Figure A.5A shows that TCRs and non-TCRs are well separated by their s_v scores, while Figure A.5B shows a clear overlap between TCRs and non-TCRs using their 1r scores. Using the 5 percentile of s_v scores on TCRs, corresponding to value 1.2577 and 95% true positive rate on TCRs, as the decision boundary, s_v scoring method achieves 0.10% false positive rate. Using the 5 percentile of 1r scores on TCRs (corresponding to -0.4459), 1r has a much higher false positive rate 8.26%. This demonstrates that s_v is very effective in distinguishing TCRs. Please note that the random sequences are not guaranteed to be true non-TCRs. However, given the random nature of these sequences, it is highly likely that they are not valid TCRs. In TCRPPO, we used 1.2577 as the threshold to quantify if a sequence is a valid TCR (i.e., $\sigma_c = 1.2577$).

Figure A.6 presents the change of s_v scores over mutations. Figure A.6A shows that as TCRs have more random mutations, their s_v scores decrease dramatically. This implies that the TCR optimization via mutation is not trivial, as a random/bad mutation can significantly decrease s_v score and easily lead to an unqualified solution. However, as Figure A.6B shows, the s_v scores do not decrease very dramatically during TCRPPO mutations, consistently with a good portion of mutated sequences being valid TCRs. This demonstrates that for this non-trivial optimization problem, TCRPPO succeeds in mutating sequences along the trajectories not far away from valid TCRs, toward final qualified sequences.